Relativno golemata molekulska masa,nedostatokot od intenzivna UV khromofora bez voopshto prisutenapsorptsionen spektar, sporata difuzija pri ambientalnatemperatura, silnata interaktsija so RP vrzanite sorbenti S8 iS18 baraat golemo vnimanie pri izvedbata na negovata analitichkadeterminatsiona metoda.TsEL NA TRUDOT Otsekogash bilo korisno da se istestira sekoja nova ideja ipromena vo HPLC operativnite parametri pri analiziranjeto naAzitrmoitsin primerotsi, so tsel kontinuirano da se podobruvaednostavnosta, shtetnosta, reprodutsibilnosta, senzitivnosta irigidnosta na analitichkiot metod, posebno koga golem brojprimerotsi treba da bidat ispitani za kratko vreme, priintenzivirani produktsioni uslovi, testiranja na rastvorlivost,studii na stabilnost, brzi evaluatsii na tekhnologii i surovini.Testiranjeto na povekje razluchni UV-transparentni puferirachkisupstantsi pri razlichni kontsentratsii i rN vrednosti, organskisolvent i nivni miksturi, razlichni statsionarni sorbenti odrazlichni firmi, sekogash produtsiraat novi momenti i situatsii,idei za kreiranje poednostavni, pobrzi, pozdravi i poevtinimetodi so podobri khromatogrami, bez zagrozuvanje na glavnitetargeti na analizite, nivnata tochnost, senzitivnost,reprodutsibilnost i maksimalna rigidnost.METODI I INSTRUMENTI Site khromatografski analizi bea izveduvani so dva razlichnimetodi na HPLC sistemi na Varian i toa modularen Pro-Star iintegriran model 920 so DAD kontrolirani so softver Galaxyverzija 1.9. Testiravme i utvrdivme mnogu razlichni kombinatsii namobilno-fazni sostojki, organski rastvoruvachi i miksturi,puferski supstantsi, jon-par reagensi i amino-modifikatori.Povekjeto od testiranite HPLC koloni bea od RP priroda, koi beanabaveni kako rN 1,5-10 i temperaturno stabilni do 60`Csorbenti. Kolonite bea produkti na Merck od tipot na LiChrospheri Purospher Star-e C8 i C18, Select B, so dolzhini 55-250mm i 5umpartikli, kako i Gemini NX-C18 od Phenomenex so dimenzii 250 x4,6mm i 5um chestichki.REZULTATI I DISKUSIJA Zavisno od tselta pri Azitromitsin determinatsionite baranjadolzhinata na kolonata beshe soodvetno izbirana za adekvatniteseparatsioni potrebi. Vo nashite ispituvanja utvrdivme dekanajevtinite rN i termorezistentnite RP vrzani koloni beaPurospher C8eStar i C18eSTAR, so dimenzii 55 kh 4 mm i 5 umpartikli na 45`S i 10ul injektsionen volumen na 214nm i dostignatasimetrija od AsUSP=1.1. Koristenata mobilna faza beshedominantno od organsko-solventna miksutra na atsetonitril imetanol, soodvetno izmeshana i pripremena so 25mMkaliumfosfaten pufer so rN 7.4. Protokot niz kolonata beshe 1.4mL/min pri shto pikot na Azitromitsinot dostigna i do 120 mAUvo probi za odreduvanje sodrzhini i do 60 mAU vo probite zaodreduvanje rastvorlivost. Za odreduvanje na srodni idegradatsioni produkti zamenata na C8eSTAR so pokhidrofobnatai poretentivna C18eSTAR, so podolgi dimenzii 125mm i najdobro250mm pokazha mnogu dobra separatsiona mokj, selektivnost istabilnost. Ovie metodi mozhat lesno da se redizajniraat vosituatsii na nedovolna selektivnost i rezolutsija so remodeliranjena vremetraenjeto na separatsijata i maksimiziranje na brojot naanalizi vo rabotniot den, odnosno vo edinitsa vreme. Sorbentiteod tipot na Purospher STAR samo ja potvrdija nivnata stabilnost iprimenlivost vo ekstremni rabotni uslovi od aspekt na rN itemperatura, potkrepeni so nivnite najniski tseni na nabavka zavakov tip na khromatografski matriksi. Eden od najbitniteatributi na ovie koloni e postignuvanjeto na perfektni simetriina pikot na Azitromitsin na khromatogramite, kako rezultat navisoko prochistenata silikatna podloga i dobrata finalnadorabotka na slobodnite silanolni grupi. REFERENTsI1. USP33 2. BP2011 3. EP785PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS poster presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONMakedonski farmatsevtski bilten 57 (dodatok), 2011TRIMETAZIDINE HPLC METHOD OPTIMIZATION - INFLUENCE OF SOLUBILITYPRESCRIBED MEDIUM ON THE SELECTIONOF ORGANIC MODIFIER ON MOBILE PHASECOMPOSITIONM.Piponski, M.Globocki, I.Mitreski, E.Lazarevska,M.Petreska, K.Andonovska, G.Trendovska.-Serafi-movskaPharmaceutical Company Replekfarm - Replek, Quality ControlDepartment, SkopjeINTRODUCTION Creation of quantitative HPLC method for Trimetazidine was governedby composition of medium for solubility testing of the solidpharmaceutical dosage forms composed of 50mM phosphate buffer atpH=6,8. This was the prescribed medium for optimal solubility whichwe had to obey, and parameter which restricted the use of acetonitrilein development of simple, reproductive and rugged method with lesssurprises in retention time instabilities and better peak symmetry.AIM OF WORKTesting of the two most common organic solvents for mobile phase inHPLC, methanol and acetonitrile in combination with phosphatebuffers with different concentrations, pH values and presence orabsence of UV-transmittable amino-modifiers, in aim to create simple,suitable accurate, reproductive and rugged method for quantificationof Trimetazidine. The peak symmetry and mobile phase simplicity wereof prime interest and targets in chromatographic solvent compositionconception. METHODS AND INSTRUMENTS All testing's were performed with Varian HPLC systems, modularconception Prostar and integrated model 920 with DAD, controlledwith Galaxy software Version 1.9. The operating conditions were UV-monitor at 215nm, at 30`C, with 1.1ml/min and 10ul injection volumes.The HPLC column used was LiChrosphere RP Select B 60, with 125 x4 mm and 5um particles. All used chemicals and reagents were PhEurgrade, products of Merck and Sigma.RESULTS AND CONCLUSIONSince the relatively high concentration of prescribed medium forsolubility testing, composed of 50mM phosphate buffer with pH=6.8,using of acetonitrile up to 30mM at pH between 2.8-3.2 region inmobile phase generated relatively asymmetric chromatogram peaksvarying at As USP values diapason 1.56-1.82. Using of suitable amino-modifiers with higher UV-transparency corrects the peak symmetry atconcentration levels higher than 0.1% v/v. But even the best UV-transparent amino-modifier at concentration levels higher than 0.1%v/v during signal measuring at 215nm can easily disturb baselineflatness. The second problem which appears after many injections isretention time fluctuations and increasing peak asymmetry, theproblems induced from great differences in compositions of mobilephase buffer and buffer in solubility medium, their concentration andpH value`s. The mobile phase 15mM phosphate buffer with nominalpH=2.8, cannot keep the chromatographic equilibrium with the morepowerful 50mM phosphate buffer with pH=6.8. Increasing theconcentration of buffer over 50mM in mobile phase is not very healthyfor columns and HPLC systems. Raising the pH of mobile phase bufferup to 6.8, stabilise the retentions but slightly improves the peaksymmetry about AsUSP=1.56. Reducing the injection volume to 5uland further to 3ul with the use of nominal pH of mobile phase buffersolves both problems with retention fluctuations and peak symmetry,but impairs the sensitivity, accuracy and precision of the method.Replacement of acetonitrile in mobile phase with methanol, showedto be much better choice for peak symmetry, retention fluctuations,lower demands of amino-modifiers, and at the end, less toxic exposureof analyst and environment to harmful chemicals.REFERENCES 1.EP7; 2.Clarkes Drug Isolation and Characterisation of DrugsTRIMETAZIDIN OPTIMIZATsIJA NAHPLC METOD - VLIJANIE NAPREDODREDEN DILUTsIONEN MEDIUMNA SELEKTsIJATA NA ORGANSKIMODIFIKATOR VO SOSTAVOT NAMOBILNATA FAZAM. Piponski, M. Globochki, I. Mitreski, E.Lazarevska, M. Petreska, G. Trendovska-Serafimovska Farmatsevtska Kompanija Replekfarm - Replek, Sektor Kontrolana Kvalitet, Skopje, R. Makedonija VOVED Kreiranjeto na kvantitativen HPLC metod za Trimetazidin beshelimitirano od sostavot na disolutsioniot medium pri testiranjetona rastvorlivosta na ovoj farmatsevtski preparat vo tsvrstadozazhna forma, koj beshe fiksiran na optimalen 50 mM fosfatenpufer so rN=6.8. Vaka preskribiraniot optimalen disolutsionenmedium beshe ogranichuvanje za koe beshe neopkhodno da bideispochituvan, a pretstavuvashe parametar koj ja otezhnuvashemozhnosta na koristenje na atsetonitrilot vo razvojot naednostaven HPLC metod, so posakuvana tochnost, senzitivnost,reprodutsibilnost i rigidnost, so pomala verojatnost naiznenaduvachki fluktuatsii na retentsiite i stabilna simetrija napikot na Trimetazidin i bazna linija. TsEL NA TRUDOT Glavna zamisla beshe da se testiraat dvata najvoobichaeni organskisolventi vo sostavite na mobilnite fazi za RP-HPLC, metanolot iatsetonitrilot, vo kombinatsii so fosfaten pufer so razlichnakontsentratsija i rN, prisustvo i otsustvo na UV-transparentniamini, so tsel da se napravi ednostaven, podoben, tochen,reproduktiven i rigiden metod za odreduvanje na Trimetazidinot.Simetrijata na khromatografskiot pik i ednostavnosta namobilnata faza bea od primarno znachenje i tsel vo86Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA poster prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOkontseptualizatsijata na mobilnata faza za HPLC. METOD I INSTRUMENTI Site testiranja bea izveduvani so Varian-ovi HPLC sistemi,modularen tip Pro-Star i integriran model 920 so DAD,kontrolirani od softver Galaxy verzija 1.9. Operativni uslovibea monitoriranje na UV signal na 215 nm na 30`S pri 1.1 ml/mini 10 ul injektsionen volumen. Koristena beshe Merck-ova kolona RPSelect B 125 x 4 mm so 5um. Site koristeni khemikalii bea so PhEurchistota nabaveni od Merck i Sigma.REZULTATI I ZAKLUChOK Poradi relativno visokata kontsentratsija na preskribiraniotdisolutsionen test medium so 50 mM fosfaten pufer so rN=6.8,koristenjeto na atsetonitril vo mobilnata faza duri i pri 30 mMpufer so rN 2.8-3.2 regionot generirashe realtivno asimetrichenpik so AsUSP=1.56-1.82. Koristenjeto na pogodni amino-modifikatori so visoka UV transparentnost pravi dobrakorektsija na simetrijata na pikot so AsUSP pod 1.5, no vokontsentratsii prisutni nad 0.1% v/v. Povisokite kontsentratsiiduri i na najdobrite amini se manifestiraat pozitivno naoblikot na pikot, no negativno na stabilnosta na baznata linijaosobeno na signal na 215 nm na koj se meri Trimetazidinot. Vtorproblem koj se pojavuva se fluktuatsiite na retentsiite po nekolkuinjektiranja i porastot na asimetrichnosta, problem indiutsiranod golemite razliki vo kontsentratsiite i rN na disolutsioniot testmedium i puferot na mobilnata faza so shto se poremetuvaekvilibriumot na khromatografskata analiza. Mobilnata faza od15mM-30mM fosfaten pufer so rN rangiranje 2.8-3.2 ne e vomozhnost da go odrzhi konstanten ekvilibriumot na prilichnopobazen i 2-3 pati pokontsentriran pufer. Pokachuvanjeto nakontsentratsijata na puferot na mobilnata faza nad 50 mM ne epreporachlivo za dolg zhivot na RP kolonite i HPLC pumpite.Doteruvanjeto na rN na mobilniot pufer na rN 6.8 go reshavaproblemot so retentsionite fluktuatsii, no ne i so namaluvanje naasimetrijata AsUSP pod 1,5. Namaluvanjeto na injektsioniotvolumen do 5ul i posebno do 3ul so koristenje na nominalniot25mM fosfaten pufer so pH=2.8 gi reshava dvata problemi sooblikot na pikot i retentsionite fluktuatsii, no ja namaluvasenzitivnosta tochnosta i pretsiznosta na metodta. Zamenata naatsetonitril so metanol vo mobilnata faza pokazha deka e mnogupodobar izbor za simetrija na pikot, stabilnost na retentsiite,potreba od pomali kontsentratsii na amini i sumarno pomalatoksikoloshka eksponiranost na personalot i okolinata. LITERATURA1.EP7; 2.Clarkes Drug Isolation and Characterisation of DrugsNEW BYLAW ON VARIATIONS OF MARKET-ING AUTHORIZATIONS FOR MEDICINALPRODUCTS IN THE REPUBLIC OF MACEDO-NIA, HARMONIZATION WITH THE LATESTEU REGULATIONVesna Nasteska-Nedanovska, Ilcho Zahariev, MarijaTrajchuleski, Rajna KostoskaBureau for Medicinal Products at the Ministry of Health of the Re-public of MacedoniaThe Bylaw on variations of marketing authorizations for medicinalproducts ("Official Gazette of the Republic of Macedonia" No. 145/08)regulates the main principles for classification of the variations, theconditions that have to be fulfilled, the legal procedures for notifica-tion or approval of the changes of marketing authorization, as well asthe manner of their implementation.